Natco Pharma to announce final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future.

Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of USD 188 million for the twelve-month period ending April, 2017, based on industry sales data.

Shares of the company gained Rs 7.3, or 0.75%, to trade at  Rs 979.80.  The total volume of shares traded  was  7,746 at the BSE (9.55 a.m., Tuesday).